Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Citi
Merck
Express Scripts
Boehringer Ingelheim
AstraZeneca
US Department of Justice
Johnson and Johnson
Cantor Fitzgerald

Generated: December 11, 2018

DrugPatentWatch Database Preview

AZEDRA Drug Profile

« Back to Dashboard

Which patents cover Azedra, and what generic alternatives are available?

Azedra is a drug marketed by Progenics Pharms Inc and is included in one NDA.

The generic ingredient in AZEDRA is iobenguane i-131. One supplier is listed for this compound. Additional details are available on the iobenguane i-131 profile page.

Summary for AZEDRA
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 7
Clinical Trials: 2
DailyMed Link:AZEDRA at DailyMed
Drug patent expirations by year for AZEDRA
Generic Entry Opportunity Date for AZEDRA
Generic Entry Date for AZEDRA*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for AZEDRA
(m-((sup 131)I)Iodobenzyl)guanidine
(m-Iodo-(sup 131)I-benzyl)guanidine
[131]I-MIBG
[131I]mIBG
131I-m-Iodobenzylguanidine
131I-MIBG
2-[(3-iodophenyl)methyl]guanidine
3-Iodobenzylguanidine
3-Iodobenzylguanidine (131I) (JAN)
77679-27-7
AC1L2FP4
AC1Q50E4
Azedra (TN)
CHEBI:135997
CHEMBL1615779
D03308
D05FQD
DTXSID30228311
Guanidine, ((3-(iodo-(sup 131)I)phenyl)methyl)-
Guanidine, ((3-iodo-131I)phenyl)methyl)-
I-131 meta-iodobenzyl guanidine
I-131 Metaiodobenzylguanidine
I-131 MIBG
Iobeguane I 131
Iobeguane I 131 [USAN]
Iobenguane ((sup 131)I)
Iobenguane ((sup 131)I) [INN]
Iobenguane (131I)
Iobenguane (131I) [INN]
Iobenguane I 131
Iobenguane I 131 (USP)
Iobenguane I 131 [USAN:USP]
Iobenguane I131
Iobenguane iobenguane ((sup 131)I)
Iobenguane Sulfate I 123 (iobenguane (131 I))
Iobenguane[131I]
Iobenguano (131 I)
Iobenguano (131 I) [Spanish]
Iobenguanum (131 I)
Iobenguanum (131 I) [Latin]
Iobenguanum (313 I) [Latin]
LS-177380
m-[123I/125I/131I]MIBG
m-131-Iodobenzylguanidine
m-Iodobenzylguanidine
M131IBG
meta-Iodobenzylguanidine (MIBG) labeled with iodine-131
Metaiodobenzylguanidine I-131
MIBG-(131 I)
MIBG[Radioiodinated]
MOLI000967
MyoMIBG-123I injection
PDWUPXJEEYOOTR-JRGAVVOBSA-N
Pheo MIBG-131I injection
PheoMIBG-I 131 (TN)
PheoMIBG-I(131) Injection
Q461L7AK4R
SCHEMBL13092741
Ultratrace iobenguane 131I
Ultratrace iobenguane I131
Ultratrace MIBG
UNII-Q461L7AK4R

US Patents and Regulatory Information for AZEDRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Progenics Pharms Inc AZEDRA iobenguane i-131 SOLUTION;INTRAVENOUS 209607-001 Jul 30, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Progenics Pharms Inc AZEDRA iobenguane i-131 SOLUTION;INTRAVENOUS 209607-001 Jul 30, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cipla
QuintilesIMS
Moodys
Express Scripts
Farmers Insurance
Queensland Health
Fuji
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.